echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Patients with advanced ovarian cancer should not be treated with immune checkpoint inhibitors!

    J Clin Oncol: Patients with advanced ovarian cancer should not be treated with immune checkpoint inhibitors!

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Epithelial ovarian cancer (OC) is the leading cause of cancer-related deaths in women worldwide: It is estimated that in 2018, the number of deaths due to OC worldwide was close to 185,000 .
    Standard treatments for advanced ovarian cancer include cytoreductive surgery and platinum-taxane combination chemotherapy.

    The number of ovarian cancer deaths worldwide due to OC in 2018 is close to 185,000

    This study aims to evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to the platinum-based combination with bevacizumab for newly diagnosed stage III-IV Efficacy of ovarian cancer .

    To evaluate the addition of human monoclonal anti-PD-L1 antibody atezolizumab to newly diagnosed stage III-IV ovarian cancer in the platinum-based combination with bevacizumab Efficacy

    This is a multicenter, placebo-controlled, randomized, double-blind phase III trial that recruited newly diagnosed patients with stage III-IV ovarian cancer who had undergone primary tumor cytoreduction or planned to undergo Neoadjuvant chemotherapy and interval surgery.
    The test patients were randomly divided into two groups 1:1, and received atuzumab (1200 mg) or placebo in addition to standard chemotherapy (paclitaxel + cisplatin + bevacizumab).
    The primary endpoints are progression-free survival and overall survival.

    PFS and OS in the intention-to-treat population and PD-L1 positive population

    PFS and OS in the intention-to-treat population and PD-L1 positive population

    From March 8, 2017 to March 26, 2019, a total of 1301 patients were recruited.
    In the intention-to-treat population, the median progression-free survival of the atuzumab group and placebo group was 19.
    5 months vs 18.
    4 months
    (hazard ratio [HR] 0.
    92, 95%CI 0.
    79-1.
    07; P=0.
    028 ).

    In the intention-to-treat population, the median progression-free survival of the atuzumab group and the placebo group was 19.
    5 months vs 18.
    4 months, respectively

    PFS in PD-L1 positive subgroup

    PFS in PD-L1 positive subgroup

    Among PD-L1 positive patients, the median progression-free survival of the atuzumab group and placebo group was 20.
    8 months vs.
    18.
    5 months
    (HR 0.
    80, 95%CI 0.
    65-0.
    99; P=0.
    038) .
    The results of the mid-term overall survival analysis showed that atuzumab had no obvious survival benefit.

    Among PD-L1 positive patients, the median progression-free survival of the atuzumab group and the placebo group were 20.
    8 months vs 18.
    5 months, respectively

    The most common grade 3-4 adverse events were neutropenia (atuzumab group vs placebo group: 21% vs 21%), hypertension (18% vs 20%), and anemia (12% vs.
    12%).

    In summary, the current analysis results of the study do not support the use of immune checkpoint inhibitors for newly diagnosed ovarian cancer patients .

    Newly diagnosed ovarian cancer using immune checkpoint inhibitor use of newly diagnosed ovarian cancer immune checkpoint inhibitors of immune

    Original source:

    Original source:

    Kathleen N.
    Moore, et al.
    org/doi/full/10.
    1200/JCO.
    21.
    00306" target="_blank" rel="noopener">Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG ​​3015/ENGOT-OV39) .
    J Clin Oncol.
    April 23, 2021 .
    https://ascopubs.
    org/doi/full/10.
    1200/JCO.
    21.
    00306

    org/doi/full/10.
    1200/JCO.
    21.
    00306" target="_blank" rel="noopener">Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050 / GOG 3015 / ENGOT-OV39)

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.